FibroGENE: A gene-based model for staging liver fibrosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS The extent of liver fibrosis predicts long-term outcomes, and hence impacts management and therapy. We developed a non-invasive algorithm to stage fibrosis using non-parametric, machine learning methods designed for predictive modeling, and incorporated an invariant genetic marker of liver fibrosis risk. METHODS Of 4277 patients with chronic liver disease, 1992 with chronic hepatitis C (derivation cohort) were analyzed to develop the model, and subsequently validated in an independent cohort of 1242 patients. The model was assessed in cohorts with chronic hepatitis B (CHB) (n=555) and non-alcoholic fatty liver disease (NAFLD) (n=488). Model performance was compared to FIB-4 and APRI, and also to the NAFLD fibrosis score (NFS) and Forns' index, in those with NAFLD. RESULTS Significant fibrosis (⩾F2) was similar in the derivation (48.4%) and validation (47.4%) cohorts. The FibroGENE-DT yielded the area under the receiver operating characteristic curve (AUROCs) of 0.87, 0.85 and 0.804 for the prediction of fast fibrosis progression, cirrhosis and significant fibrosis risk, respectively, with comparable results in the validation cohort. The model performed well in NAFLD and CHB with AUROCs of 0.791, and 0.726, respectively. The negative predictive value to exclude cirrhosis was>0.96 in all three liver diseases. The AUROC of the FibroGENE-DT performed better than FIB-4, APRI, and NFS and Forns' index in most comparisons. CONCLUSION A non-invasive decision tree model can predict liver fibrosis risk and aid decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×
“The FIB-4 index was calculated as follows: age (years) AST (IU/L)/(platelets (10(9)/L) (alanine aminotransferase: ALT(IU/L)) [21].”
MethodWai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Review: a gentle introduction to imputation of missing values.
Donders, A. R. T., van der Heijden, G. J. M. G., Stijnen, T., & Moons, K. G. M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.014 · Cited by 2,582
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“The extent of liver fibrosis is the most important predictor of long-term outcomes in chronic liver diseases, and hence the critical variable for rational decision making [42,43], including for variceal and hepatocellular carcinoma screening.”
BackgroundUpdated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445 · cited 2×
“The values for the upper limit of normal for AST were set according to the International Federation of Clinical Chemistry, that is, 35 U/L for men and 30 U/L for women [24].”
BackgroundMethodModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866 · cited 1×
“Irrespective of the underlying disease, hepatic fibrosis culminating in cirrhosis is the principal cause of chronic liver disease related morbidity and mortality [1].”
BackgroundApplication of artificial neural networks to clinical medicine
Baxt, W. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91804-3 · Cited by 677 · cited 1×
“For the formulation of predictive models, a search for the optimal models was conducted by applying several machine learning techniques, including Multivariate Logistic Regression Analysis (MLRA), Artificial Neural Network (ANN), Decision Tree (DT) and Nearest Neighborhood (KNN) [27–29].”
MethodVergouwe, Y., Steyerberg, E. W., Eijkemans, M. J. C., & Habbema, J. D. F. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.06.017 · Cited by 636 · cited 1×
“of events (significant fibrosis), sample size estimation was calculated with standard formulas based on the normal distribution [36].”
MethodTHE INTERNATIONAL CONFERENCE ON HARMONIZATION GOOD CLINICAL PRACTICE GUIDELINE
Dixon, J. R. (1999) · Quality Assurance · doi:10.1080/105294199277860 · Cited by 504 · cited 1×
“The study was conducted in accordance with ethical guidelines of the International Conference on Harmonization Guidelines for Good Clinical Practice [18].”
MethodDas, A., Ben-Menachem, T., Cooper, G. S., Chak, A., Sivak, M. V., Gonet, J. A., & Wong, R. C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14568-0 · Cited by 208
Cited by
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Self-citationThe Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Self-citationMAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T. (2020) · Liver International · doi:10.1111/liv.14675 · Cited by 401
“ALT (U/L) 19 (14-29) 4-122 22 (16-33) 4-188 .”
InfluentialAdvances in non-invasive assessment of hepatic fibrosis
Loomba, R., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 345
Self-citationGenetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 308
Self-citation
Metadata
- Authors
- Eslam, M., Hashem, A. M., Romero-Gomez, M., Berg, T., Dore, G. J., Mangia, A., Chan, H. L. Y., Irving, W. L., Sheridan, D., Abate, M. L., Adams, L. A., Weltman, M., Bugianesi, E., Spengler, U., Shaker, O., Fischer, J., Mollison, L., Cheng, W., Nattermann, J., Riordan, S., Miele, L., Kelaeng, K. S., Ampuero, J., Ahlenstiel, G., McLeod, D., Powell, E., Liddle, C., Douglas, M. W., Booth, D. R., & George, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 64
- Issue
- 2
- Pages
- 390-398
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2175436961
- Cited by
- 75
- References
- 10
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.